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Aims Oxidative processes and vascular inﬂammation underlying atherosclerosis lead to an accumulation of lysophosphati-
dic acid (LPA) molecules in the atheromatous intima. LPA, a platelet-activating component of human atherosclerotic
plaques, possibly contributes to atherothrombus formation after plaque rupture. Human platelets express mRNA for
the G protein-coupled receptors LPA1–7that derive from megakaryocytes. The aim of our study was to identify the
functional LPA receptor(s) in human platelets by silencing individual LPA receptors in megakaryocytic (MK) cells.
Methods
and results
We studied shape change of two human MK cell lines (Meg-01, Dami) by turbidometry, phase-contrast and scanning
electron microscopy. They showed upon LPA stimulation a rapid, Rho-kinase-mediated shape change similar to that
of human platelets. By qRT–PCR analysis we found expression of LPA1–7in both cell lines; LPA4 and LPA5 were the
most abundant receptor transcripts. In both Meg-01 and Dami cells, the rank order of activation by LPA species was
similar to that found in platelets: alkyl-LPA 18:1 . alkyl-LPA 16:0 . acyl-LPA 18:1 ..alkyl-LPA 18:0. Knock-down
of individual LPA receptors by siRNA showed that LPA-mediated activation of MK cells was mediated by LPA5, but
not by LPA1–4,6,7. Importantly, we found that human atherosclerotic plaque and lipid-rich core induced shape change
of Dami cells, and that this effect was inhibited after LPA5 silencing.
Conclusions Our ﬁndings indicate that LPA5 mediates LPA-induced shape change of MK cells and support its involvement in ather-
osclerotic plaque and lipid-rich core-mediated platelet activation. This receptor could be an attractive novel target for
antithrombotic therapy.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
During the progression of atherosclerosis, oxidative processes and
vascular inﬂammation lead to an accumulation of lysophosphatidic
acid (LPA) in the arterial intima.
1–3 LPA consists of various molecular
species with different platelet-activating potency.
2,4–7 In atherosclero-
tic plaques, LPA molecules of high platelet-activating potency have
been identiﬁed that mediate the initial platelet response—shape
change—by the plaque lipid-rich core, and induce synergistically
with other platelet stimuli (ADP, epinephrine) aggregation of isolated
platelets.
7 Moreover, LPA at concentrations approaching those found
in vivo induces platelet activation in whole blood.
5 Thus, after rupture
of lipid-rich atherosclerotic plaques, LPA exposed to circulating plate-
lets might contribute to the formation of intravascular thrombi
responsible for acute coronary syndrome, myocardial infarction, and
ischaemic stroke.
1,2
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surface. The signal emitted by the activated receptor(s) is transduced
by G12/13 proteins to activation of Rho, Rho-kinase, LIM-kinase 1, and
subsequent phosphorylation of cytoskeletal proteins such as myosin
light chain, moesin, and coﬁlin.
8–11 These biochemical events cause
speciﬁc actin remodelling leading to platelet shape change. Cytosolic
Ca
2+ increase and Rac activation are not involved in LPA-induced
shape change.
9,12
LPA GPCRs are divided into two subfamilies: one is composed
of three members, LPA1, LPA2, and LPA3 belonging to the Endo-
thelial Differentiation Gene (EDG-) subfamily
2 and the second is
the purinoreceptor (P2Y) cluster of GPCRs. This subfamily has
grown considerably in recent years, and it now consists of ﬁve
LPA receptors: LPA4 (GPR23), LPA5 (GPR92), LPA6 (GPR87),
LPA7 (P2Y5), and LPA8 (P2Y10).
13–17 However, there remain
some doubts whether LPA4,6,8 are functional LPA receptors
or not.
18,19
Human platelets express mRNA for LPA1–7, and the most abun-
dant are LPA4 and LPA5 transcripts.
20 The expression of LPA recep-
tors at the protein level is unknown due to the lack of speciﬁc
antibodies. A previous study has suggested a role of LPA1 and LPA3
in LPA-induced platelet activation,
7 whereas two recent studies
favour the involvement of other receptors such as LPA4 and LPA5
in LPA-induced platelet shape change.
20,21 However, ﬁrm evidence
that these receptors mediate platelet stimulation by LPA and plaque
lipid-rich core is lacking: The LPA response of platelets did not
match with the pharmacological properties of the heterologously
expressed LPA4 and LPA5 receptors,
20 and the pharmacological
receptor agonists and antagonists used were not selective for
LPA5.
21 The role of the newly discovered LPA receptors LPA6
(GPR87) and LPA7 (P2Y5) in LPA-mediated platelet activation has
not been studied so far. Therefore, the functional platelet LPA recep-
tor(s) remains elusive.
In the present study, we set out to identify the functional platelet
LPA receptor by applying siRNA interference technology to selec-
tively knock-down LPA1–7 receptors in megakaryocytes. Platelets
derive from megakaryocytes, and, based on studies showing the pres-
ence of various platelet receptors on the surface of megakaryocytes,
we reasoned that megakaryocytes might also express functional plate-
let LPA receptors. In line with this assumption, a previous study used
human megakaryocytic (MK) cell lines to discover the P2Y1 receptor
in platelets.
22
2. Methods
2.1 Materials
LPA species were purchased from Avanti Polar Lipids (Alabaster, AL,
USA) and Echelon Biosciences (Salt Lake City, UT, USA). Human throm-
bin (T-7009) was from Sigma-Aldrich. Fatty acid-free bovine serum
albumin was obtained from Fluka (Taufkirchen, Germany). The RNeasy
mini kit, Omniscript reverse transcriptase kit, and QuantiFast SYBR
Green RT–PCR kit were from Qiagen (Hilden, Germany). Alexa
Fluor-546 phalloidin was from Molecular Probes (Eugene, OR). Y-27632
[(+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide
dihydrochloride] was obtained from Merck Biosciences GmbH (Schwal-
bach, Germany), and Collagen (Horm
w) was obtained from Nycomed
Pharma (Munich, Germany).
2.2 Isolation of human carotid atherosclerotic
plaques and lipid-rich core
The investigation conforms with the principles outlined in the Declaration
of Helsinki for use of human tissue. Atherosclerotic tissue specimens were
obtained from patients who had undergone operations for high-grade
carotid stenosis as described previously.
7,23 Written consent of the
patients was obtained, and the study was approved by the Ethics Commit-
tee of the Faculty of Medicine of the University of Munich. Atheromatous
plaques were carefully dissected from other regions of the atherosclerotic
tissue specimens.
24 The plaque samples were weighed, homogenized in an
ice-cold N2 saturated buffer (150 mM NaCl, 1 mM EDTA, pH 7.4), and
stored at 2808C. In some atheromatous plaque specimens, it was poss-
ible to excise the lipid-rich core from the surrounding ﬁbrous capsule.
The concentrations of atheromatous plaque and lipid-rich core were
adjusted to 50 and 100 mg wet weight/mL, respectively.
2.3 Cultures of MK cell lines and measurement
of shape change
Dami and Meg-01 (American Type Culture Collection, ATCC) cells were
grown in plastic culture ﬂasks in RPMI 1640 medium supplemented with
10% FCS, 100 U/mL of penicillin, and 100 U/mL of streptomycin at
378C in a humidiﬁed atmosphere with 5% CO2. They were subcultured
twice a week to maintain a concentration of 0.5 × 10
6cells/mL.
For measurement of shape change, MK cells were washed twice in PBS
and resuspended in HEPES–Tyrode’s buffer (15 mM HEPES, 140 mM
NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.1% glucose, 3.75 mM NaH2PO4,
24 mM NaHCO3, pH 7.5) to obtain a cell density of 4 × 10
6cells/mL.
Shape change of the stirred (1100 rpm) MK suspension was measured
by the decrease of light transmission at 378C in a LABOR aggregometer
(Fresenius, Germany).
25,26
2.4 Microscopy of ﬁxed and living cells
Shape change of Dami and Meg-01 cells was morphologically examined
after phalloidin staining of F-actin as described previously.
25 Phase contrast
Figure 1 Expression of LPA1–7 transcripts in Dami and Meg-01
cells. (A) LPA1–7 receptor mRNA expression as shown by PCR.
(B) Relative abundance of LPA receptor transcripts in Dami and
Meg-01 cell lines measured by quantitative RT–PCR. Values rep-
resent the mean+SD from three different experiments.
A.L. Khandoga et al. 158and ﬂuorescence microscopy was performed using a Nikon TE2000
microscope. The imaging of living cells was carried at 378C in an incu-
bation chamber. The images were taken with a cooled CCD camera
and analysed using the manufacturer’s software NIS elements 3.0.
2.5 Scanning electron microscopy
Dami and Meg-01 cells were prepared as described above and samples
were exposed to LPA or solvent for 2 min whilst stirring in the aggreg-
ometer and then ﬁxed with 3% glutaraldehyde in 0.1 M sodium phosphate
buffer (pH 7.3). Samples were then ﬁltered through a 0.2-mm Nucleopore
ﬁlter followed by 10 mL of preﬁltered distilled water. Filters were dehy-
drated with graded ethanol (from 35 to 100%), soaked for 10 min in hex-
amethyldisilazane, dried, and coated with a thin layer of gold (Bal-Tec
Sputter Coater SCD 050, Balzers Union AG, Balzers, Liechtenstein).
Imaging was performed using a Zeiss Supra 55 VP scanning electron
microscope.
2.6 Quantitative PCR of LPA receptor mRNA
in MK cells
Total cellular RNA was extracted from Dami or Meg-01 cells using the
RNeasy mini kit (Qiagen), treated with RNase-free DNase. For the
reverse-transcription synthesis of cDNA, the Omniscript reverse tran-
scriptase kit with random hexamer primers was used. Quantitative RT–
PCR was then performed in a Real-Time PCR iCycler using the QuantiFast
SYBR Green RT–PCR Kit according to the manufacturer’s protocols.
The primer sets were as follows: LPA1 (forward) CACAGTCAG
CAAGCTGGTGATG and (reverse) TCTCCGAGTATTGGGTCCTG;
LPA2 (forward) CGCACAGCCCGA CTTTCACTT and (reverse) CA
CAATGAGCATGACCACGC; LPA3 (forward) GGCACATGTCAAT
CATGA GG and (reverse) ATGATGAGGAAGGCCATGAG; LPA4
(forward) ACCACCACCTGCTTTGAAGG and (reverse) AGAGTTG
CAAGGCACAAGGT; LPA5 (forward) CTCGGTGGTGAGCGTGTA-
CATG and (reverse) GCGTAGCGGTCCACGTTGAT; LPA6/GPR87
(forward) GGCCAAGAGAGTCACAATTCAGG and (reverse) CAG
CGTCATTATGAGGTCTGC; LPA7/P2Y5 (forward) AAGCAAAATAA
ACAAAACTAA and (reverse) GTCT GTAGGTTATGCTGAATAAAA;
b-actin (forward) CACCACACCTTCTACAATGAGC and (reverse)
CAGAGGCGTACAGGGATAGC.
The RT–PCRs were performed in triplicate on each cDNA template
along with triplicate reactions of the housekeeping gene, b-actin. Negative
control was obtained by performing real-time RT–PCR without cDNA.
All RT–PCR products were veriﬁed by melting-curve analysis and
agarose gel electrophoresis. The LPA receptor mRNA expression levels
Figure 2 LPA induces shape change of Dami and Meg-01 cells. (A) LPA-induced shape change of Dami cells is Rho-kinase mediated. Dami cells were
incubated with solvent or 20 mM Y-27632 for 20 min before exposure to acyl-LPA (25 nM). The arrow indicates the point of addition of LPA. Shape
change was recorded as a decrease of light transmission. Tracings shown are representative for three experiments. (B) Morphological changes of
human MK cell lines upon stimulation with the LPA. Dami cells or Meg-01 cells were stimulated with solvent or acyl-LPA 16:0 (50 nM) for 1 min
at 378C in an aggregometer while stirring, then ﬁxed, permeabilized, stained with Alexa 546 phalloidin for F-actin, and visualized by phase-contrast
(grey) and ﬂuorescent (red) microscopy. Bar equals 10 mm. (C) Quantiﬁcation of activated cells after contrast microscopy. Cells were counted at ×40
magniﬁcation, and the total numbers of cells and activated cells in ﬁve randomly selected ﬁelds were determined. Values are mean+SD (n ¼ 3).
(D) Scanning electron micrographs of untreated and LPA-stimulated Dami and Meg-01 cells. Bar equals 2 mm.
Identiﬁcation of LPA5 as potential antithrombotic target 159were determined by the comparative Ct method, normalizing expression
to b-actin.
2.7 siRNA transfection
The human LPA receptors siGENOME SMARTpool siRNAs and control
non-targeting siRNA were obtained from Dharmacon (Lafayette, CO,
USA). Sequences of siRNA against LPA1–7 are listed in Supplementary
material online, Table. siRNA transfection was performed as described
previously.
27 Brieﬂy, prior to this procedure, cells were pelleted by cen-
trifugation at 200 g for 5 min then washed twice with PBS. After a ﬁnal
centrifugation, cells were resuspended at 5 × 10
5cells/mL in serum/
antibiotic-free RPMI 1640 medium with oligofectamine-complexed
siRNA duplexes. Transfections were carried out twice with a 24-h interval
and fetal calf serum replenished to 10% 4 h post-transfection. The cells
were used for experiments at 72 h after transfection. The percentage of
relative gene expression was calculated as the relative amount of LPA
receptor mRNA in cells transfected with LPA receptor targeting siRNA
compared with that of cells transfected with the non-targeting control
siRNA which was set to 100%.
2.8 Statistical analysis
Values given are mean+SD. Signiﬁcant difference was determined by the
paired Student’s t-test or other tests as appropriated. A P-value of ,0.05
was considered statistically signiﬁcant. Logarithmic median effective con-
centrations (LogEC50) were calculated from respective binding curves
using the web-based BioDataFit software.
3. Results
3.1 Expression of LPA receptor mRNAs
in human MK cell lines
Both Dami and Meg-01 cells expressed LPA1–7 transcripts. Agarose
gel electrophoresis of the PCR products revealed fragments of the
expected sizes (Figure 1A). DNA sequencing of the PCR products
conﬁrmed the correct sequences of the LPA receptors. Similar to
platelets, quantitative RT–PCR analysis of LPA receptors showed
that LPA4 and LPA5 receptors were the most abundant in Dami
and Meg-01 cell lines (Figure 1B).
20 Expression of LPA4 transcripts
was similar in both cell lines, whereas LPA5 was more prominent in
Dami cells. Interestingly, in Dami cells, LPA2 receptor expression
was also pronounced, and similar to that of LPA4.
3.2 The effect of LPA on MK cell lines
In order to analyse whether LPA can also activate MK cell lines, stirred
Dami and Meg-01 cell suspensions were exposed to LPA, and shape
change was measured by the decrease of light transmission in an
aggregometer. Figure 2A shows that LPA (50 nM) rapidly induced
shape change of Dami cells which was maximum within 60 s. More-
over, similar to platelets, LPA-mediated shape change in MK cells
was reversible (see Supplementary material online. Figure S1).
1
Previously it has been shown that LPA stimulates platelet shape
change through activation of the Rho/Rho-kinase pathway.
9,10 There-
fore, we examined whether Dami cell activation by LPA was also Rho-
kinase dependent. Pre-incubation of Dami cells with the Rho-kinase
inhibitor Y-27632 (20 mM) completely inhibited LPA-induced shape
change (Figure 2A). Moreover, similar to platelets, the pre-incubation
of MK cells with albumin dose-dependently inhibited the LPA-elicited
shape change response with an IC50 of 2.84+1.06 and 4.14+
1.02 mM, in Dami and Meg-01 cells, respectively (see Supplementary
material online, Figure S2).
20
To observe the shape change morphologically, MK cells were ﬁxed
and visualized by phase-contrast and ﬂuorescence microscopy after
F-actin staining with Alexa Fluor 546 phalloidin (Figure 2B). Unstimu-
lated Dami and Meg-01 cells (control) were spherical and only a few
cells had pseudopods (Figure 2B and C). Upon LPA stimulation, the
cell surface became irregular; Meg-01 cells formed mainly multiple
pseudopods and extensive membrane blebbing at several sites on
Figure 3 Concentration–response curves of Dami and Meg-01
cells stimulated by various LPA species. Suspensions of Dami (A)
and Meg-01 (B) cells were stirred at 378C for 2 min and then
exposed to increasing concentrations of LPA species. The decrease
in light transmission was measured. Values represent the mean+SD
from three different experiments.
.............................................................
....................................................................................
Table 1 Comparison of activities of different molecular
species of LPA on MK cells and platelets
LPA species LogEC50 (mM)
Dami Meg-01 Platelets
20
Alkyl-LPA 18:1 22.46+0.29 22.02+0.14 22.80+0.13
Alkyl-LPA 16:0 22.09+0.10 21.76+0.15 22.30+0.30
Acyl-LPA 18:1 21.84+0.04 21.48+0.09 22.18+0.48
Alkyl-LPA 18:0 21.52+ 0.08 21.16+0.07 21.66+0.28
Dami and Meg-01 LogEC50 values were calculated from the concentration–response
curves using the web-based BioDataFit software (n ¼ 3, mean+SD). Platelet EC50
values are from Ref. 20.
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trusions (Figure 2B). Scanning electron microscopy of MK cells showed
that untreated cells had numerous microvillous projections; after LPA
activation, Dami and Meg-01 cells formed multiple pseudopods and
membrane blebs, and Dami cells produced long protrusions
(Figure 2D).
To observe the shape change in more detail, live microscopy of
Dami and Meg-01cells was performed (see Supplementary material
online, Videos). Also under non-stirring conditions, LPA rapidly
induced shape change of MK cells within 2 min. Dami cells in contrast
to Meg-01 dramatically formed long protrusions (1–3 per cells).
Meg-01 cells produced mostly short pseudopods and extensive mem-
brane blebbing at several sites of the cell. By analysis of Dami cells
before and 2 min after LPA stimulation, we found that the cell diam-
eter was reduced from 12.64+1.32 to 11.4+1.93 mm( P ¼ 0.019),
and the length of protrusions was 10+3 mm.
3.3 MK cell lines and platelets show similar
structure–activity relationships
The LPA response curves of platelets show a preference of alkyl-LPA
over acyl-LPA.
2 We studied LPA molecular species on MK cells which
had shown different platelet activating potency.
7,20 The concen-
tration–response curves of four LPA species tested were similar in
the two MK cell lines. The rank order of potency was: alkyl-LPA
18:1 . alkyl-LPA 16:0 . acyl-LPA 18:1 . alkyl-LPA 18:0 (Figure 3,
Table 1). The EC50 values of the different LPA species were in a
similar range in Dami, Meg-01, and platelets (Table 1).
3.4 LPA induces Dami and Meg-01 cell
activation through the LPA5 receptor
Since Dami and Meg-01 cells express all known LPA receptors, we
applied the siRNA interference technology to identify the functionally
relevant LPA receptor subtypes in MK cell lines. LPA receptors were
down-regulated by speciﬁc siRNAs targeting LPA1–7. Real-time PCR
analysis showed a 60–80% reduction of LPA1–7 in Dami cells
(Figure 4A). The effect of LPA receptor down-regulation was analysed
by shape change measurement in the aggregometer as well as by
phase-contrast microscopy (Figure 4B–D). Silencing of the LPA5
receptor reduced the LPA-induced activation of Dami cells to 34+
10% of control (P , 0.001; n ¼ 6). In addition, down-regulation of
LPA5 in Meg-01 cells also inhibited the LPA-induced activation
(Figure 4D). Silencing of LPA5 receptor had no effect on
Figure 4 LPA5 knock-down inhibits shape change of Dami and Meg-01 cells. (A) LPA1–7 mRNA levels after selective receptor knock-down. Dami
cells were treated for 72 h with speciﬁc LPA receptor siRNA or non-target siRNA. The expression level was analysed by RT–PCR. (B) Effect of LPA
receptor silencing on LPA-induced Dami cell shape change as measured by the decrease of light transmission. Dami cells treated for 72 h with speciﬁc
LPA receptor siRNA or non-target siRNA (control) were exposed to acyl-LPA 16:0. Values are mean+SD (n ¼ 3; signiﬁcance was tested by
ANOVA, Bonferroni was used as post-test *P , 0.001). (C) Quantiﬁcation of activated cells after contrast microscopy. Dami cells treated for 72 h
with speciﬁc LPA5 receptor siRNA or non-target siRNA were exposed to acyl-LPA 16:0. Cells were ﬁxed and counted at ×40 magniﬁcation, and
the total numbers of cells in 10 randomly selected ﬁelds were determined. Values are mean+SD (n ¼ 3). (D) Representative tracings of LPA-induced
shape change of Dami and Meg-01 cells after treatment with speciﬁc LPA receptor siRNA or non-target siRNA.
Identiﬁcation of LPA5 as potential antithrombotic target 161thrombin-induced shape change in both MK cell lines (see Supplemen-
tary material online, Figure S3).
3.5 The involvement of LPA5 receptor
in lipid-rich core- and plaque-induced
MK cell activation
Human plaque homogenates contain platelet-activating collagenous
structures and various LPA molecules which activate platelets,
whereas the plaque lipid-rich core contains LPA species but lacks col-
lagenous structures.
7,23,28 In order to identify the possible role of
LPA5 in plaque-mediated platelet activation, we ﬁrst analysed
whether lipid-rich core, plaque, and collagen can induce shape
change of Dami cells. We used concentrations of these stimuli that
induced maximal platelet activation as shown in previous studies.
7,23
Plaque and lipid-rich core induced shape change as observed by the
decrease in light transmission, phase-contrast microscopy, and scan-
ning electron microscopy (Figure 5A and C; see Supplementary
material online, Figure S4). In contrast, collagen did not activate
these cells (Figure 5A). These results indicate that lipids such as LPA
rather than collagen may mediate Dami cell shape change by
plaque. Indeed, shape change of Dami cells induced by the lipid-rich
core and plaque was inhibited after down-regulation of LPA5
(Figure 5B and C). Thus, the LPA5 receptor appears to mediate
plaque-induced activation of Dami cells.
4. Discussion
The present study was undertaken to identify the functional LPA
receptor(s) in human MK cells. We used these cells as a model
system for platelets to allow a conclusion about the functional platelet
LPA receptor. Previously, human MK cell lines have been successfully
used to identify the P2Y1 receptor in platelets.
22 In the present study,
we found that two human MK cell lines (Dami and Meg-01) behaved
similarly in many ways to platelets in their response to LPA: (a) the
two MK cell lines showed a rapid shape change after exposure to
low LPA concentrations; (b) the shape change was Rho-kinase
mediated; (c) low concentrations of albumin inhibited the LPA-elicited
shape change of these cells with a low IC50 comparable to the IC50 in
platelets; and (d) we also studied the activity of four different LPA
species in these MK cells and found that the structure–activity
relationships of Dami and Meg-01 cells were not only similar to
each other, but they were also comparable with that of platelets.
20
These similarities argue for the existence of the same functional
LPA receptor(s) on the surface of the two MK cell lines and platelets.
Figure 5 Atherosclerotic plaque- and lipid-rich core-induced activation of Dami cells is mediated by LPA5.( A) Shape change of Dami cells were
measured after exposure to homogenate of lipid-rich core (2.5 mg wet weight/mL), of plaque homogenate (5 mg wet weight/mL), or to collagen
(10 mg/mL). The arrow indicates the point of addition of substance. (B) After 72 h of treatment with speciﬁc LPA5 receptor siRNA or non-target
siRNA, Dami cells were stimulated with plaque homogenate or lipid-rich core. Shape change was recorded as decrease in light transmission. Tracings
shown are representative for three experiments. (C) Morphological changes induced in Dami cells upon stimulation with the plaque and plaque
lipid-rich core. After 72 h of treatment with speciﬁc LPA5 receptor siRNA or non-target siRNA, Dami cells were stimulated with solvent, homogenate
of lipid-rich core (2.5 mg wet weight/mL) or plaque homogenate (5 mg wet weight/mL)) for 2 min at 378C in an aggregometer while stirring, then
ﬁxed, and visualized by phase-contrast microscopy. Bar equals 10 mm.
A.L. Khandoga et al. 162Moreover, in both MK cell lines, we found transcripts for LPA1–7,
and—similar to platelets—the LPA5 and LPA4 transcripts were the
most abundant in both cell lines. The higher expression of LPA5 in
Dami cells compared with that in Meg-01 cells may be due to different
stages of maturation of the cell lines, i.e. Dami cells are more
mature.
29,30
In our previous studies, the identiﬁcation of the functional LPA
receptor(s) in platelets was carried out by using a pharmacological
approach, and ﬁrm evidence that the LPA5 receptor mediates platelet
stimulation by LPA and plaque lipid-rich core was lacking.
20,21 In the
present study, we applied siRNA interference technology which
allowed the effective and speciﬁc silencing of individual LPA1–7recep-
tors in the MK cells. We found that LPA-induced activation was signiﬁ-
cantly inhibited after down-regulation of LPA5 in both cell lines but
not after silencing of LPA1–4,6,7, indicating that LPA5 is the functional
receptor mediating LPA-induced shape change. In contrast to Meg-01
cells, the effect of LPA in LPA5 down-regulated Dami cells was not
completely abolished. This might be because Dami cells have a
higher expression of LPA5 when compared with Meg-01 cells and
that they still had some functional LPA5 receptors on their surface
after LPA5 silencing.
It has been shown that LPA mediates plaque lipid-rich core- and
plaque-induced platelet shape change.
1,7 LPA contained in the
lipid-rich core consists of several molecular species containing differ-
ent fatty acids in acyl- and alkyl-linkage.
1 The various LPA species acti-
vate platelets with different potencies.
6,7,20 We have demonstrated in
this study that atherosclerotic plaques and the plaque lipid-rich core
are capable of inducing shape change of Dami and Meg-01 cells.
This effect was inhibited after LPA5 depletion. We conclude that
our ﬁndings provide strong evidence that LPA5 is the functional plate-
let LPA receptor stimulated by the lipid-rich core of atherosclerotic
plaques. This receptor might be a suitable target for antithrombotic
therapy.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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